Catalent Pharma Solutions Fined After Contact With Olanzapine Leads To Dermatitis
12/22/2010 8:31:51 AM
In-Pharma Technologists -- Catalent has been fined after contact with olanzapine led to employees developing dermatitis, an incident the company “deeply regrets”. The UK Health and Safety Executive (HSE) prosecuted Catalent after 10 employees at its Swindon plant developed allergic contact dermatitis, an irreversible skin condition. Catalent pleaded guilty and was ordered to pay a £50,000 ($77,000) fine and £50,000 in costs.
comments powered by